Floatz logo

ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166

Lip Cancer Stage I

Klus Pharma Inc.antibody_drug_conjugatePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Lip Cancer Stage I cohort.

Asset / SponsorPhaseRating
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
VM Oncology, LLC
Phase 1/2CCC
Pembrolizumab
VM Oncology, LLC
Phase 1/2CCC

Same molecule, other indications

ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166 is also rated in:

HER2 positive breast carcinomaDormant
B
Indicative ·
60 / 100
View asset →
breast cancerDormant
B
Indicative ·
56 / 100
View asset →
tumor of salivary glandDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →